Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Analysts

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $42.67.

Separately, Wedbush restated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, May 14th.

Scholar Rock Trading Down 2.4%

SRRK traded down $0.71 during trading hours on Tuesday, reaching $29.13. The company's stock had a trading volume of 1,368,000 shares, compared to its average volume of 1,270,141. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The stock has a market cap of $2.77 billion, a PE ratio of -12.40 and a beta of 0.37. The business's 50-day moving average is $30.38 and its 200-day moving average is $36.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter in the previous year, the business posted ($0.59) earnings per share. As a group, equities research analysts predict that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey S. Flier sold 6,075 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $29.73, for a total transaction of $180,609.75. Following the sale, the director now owns 24,070 shares of the company's stock, valued at approximately $715,601.10. This represents a 20.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. This represents a 56.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 181,798 shares of company stock worth $6,284,738 over the last ninety days. Corporate insiders own 13.30% of the company's stock.

Institutional Trading of Scholar Rock

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock worth $205,013,000 after acquiring an additional 708,817 shares during the period. Principal Financial Group Inc. purchased a new position in Scholar Rock in the fourth quarter valued at $274,000. Blackstone Inc. purchased a new position in Scholar Rock in the fourth quarter valued at $910,000. Rhumbline Advisers increased its holdings in Scholar Rock by 13.2% in the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock valued at $4,895,000 after buying an additional 13,247 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Scholar Rock in the fourth quarter valued at $2,625,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.